{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:10:37Z","timestamp":1793729437274,"version":"4.6.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21961142009"],"award-info":[{"award-number":["21961142009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501725"],"award-info":[{"award-number":["82501725"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hangzhou Natural Science Foundation","award":["2024SZRYBH090002"],"award-info":[{"award-number":["2024SZRYBH090002"]}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY1032"],"award-info":[{"award-number":["2025KY1032"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is a progressive neurodegenerative disorder characterized by the pathological accumulation of \u03b1-synuclein aggregates and the selective degeneration of dopaminergic neurons in the substantia nigra. Growing evidence implicates dysfunction of the ubiquitin-proteasome system (UPS), a critical regulator of protein homeostasis, in the pathogenesis of PD through impaired clearance of toxic protein species. As key components of the UPS, deubiquitinating enzymes (DUBs) counterbalance ubiquitin ligase activity by cleaving ubiquitin chains from substrate proteins, thereby playing pivotal roles in maintaining protein turnover and regulating cellular signaling pathways. Notably, emerging research has demonstrated that specific DUBs are intimately involved in modulating multiple PD-related pathological processes, including \u03b1-synuclein aggregation, mitochondrial oxidative stress, iron homeostasis, and neuronal survival. These findings suggest DUBs as promising therapeutic targets for PD intervention. This review comprehensively summarize the pathophysiological roles of PD-associated DUBs, their molecular mechanisms in disease progression, and recent advances in the development of DUB inhibitors as potential disease-modifying therapies for PD.<\/jats:p>","DOI":"10.1186\/s10020-025-01389-x","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:21:42Z","timestamp":1762503702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Deubiquitinating enzymes in parkinson\u2019s disease: molecular mechanisms and therapeutic potential"],"prefix":"10.1186","volume":"31","author":[{"given":"Yarong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiya","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"1389_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1242\/jcs.183954","volume":"129","author":"M Akutsu","year":"2016","unstructured":"Akutsu M, Dikic I, Bremm A. Ubiquitin chain diversity at a glance. J Cell Sci. 2016;129:875\u201380.","journal-title":"J Cell Sci"},{"key":"1389_CR2","doi-asserted-by":"publisher","first-page":"E4688","DOI":"10.1073\/pnas.1523597113","volume":"113","author":"Z Alexopoulou","year":"2016","unstructured":"Alexopoulou Z, et al. Deubiquitinase Usp8 regulates \u03b1-synuclein clearance and modifies its toxicity in lewy body disease. Proc Natl Acad Sci U S A. 2016;113:E4688\u20134697.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1389_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1471-4159.2004.02485.x","volume":"90","author":"HC Ardley","year":"2004","unstructured":"Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in parkinson\u2019s disease. J Neurochem. 2004;90:379\u201391.","journal-title":"J Neurochem"},{"key":"1389_CR4","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41418-024-01342-1","volume":"31","author":"S Bian","year":"2024","unstructured":"Bian S, et al. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization. Cell Death Differ. 2024;31:1202\u201318.","journal-title":"Cell Death Differ"},{"key":"1389_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nature13418","volume":"510","author":"B Bingol","year":"2014","unstructured":"Bingol B, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature. 2014;510:370\u20135.","journal-title":"Nature"},{"key":"1389_CR6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/15384101.2019.1593646","volume":"18","author":"T Bonacci","year":"2019","unstructured":"Bonacci T, Emanuele MJ. Impressionist portraits of mitotic exit: APC\/C, K11-linked ubiquitin chains and Cezanne. Cell Cycle (Georgetown Tex). 2019;18:652\u201360.","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"1389_CR7","doi-asserted-by":"publisher","first-page":"19209","DOI":"10.1074\/jbc.M117.815126","volume":"292","author":"M Boselli","year":"2017","unstructured":"Boselli M, et al. An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces Tau elimination in cultured neurons. J Biol Chem. 2017;292:19209\u201325.","journal-title":"J Biol Chem"},{"key":"1389_CR8","doi-asserted-by":"crossref","unstructured":"Buneeva O, Medvedev A. (2024) Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson\u2019s Disease. Int J Mol Sci 25.","DOI":"10.3390\/ijms25021303"},{"key":"1389_CR9","doi-asserted-by":"crossref","unstructured":"\u00c7etin G, Klafack S, Studencka-Turski M, Kr\u00fcger E, Ebstein F. (2021) The Ubiquitin-Proteasome System in Immune Cells. Biomolecules 11.","DOI":"10.3390\/biom11010060"},{"key":"1389_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fphys.2020.00535","volume":"11","author":"J Chakraborty","year":"2020","unstructured":"Chakraborty J, Ziviani E. Deubiquitinating enzymes in parkinson\u2019s disease. Front Physiol. 2020;11:535.","journal-title":"Front Physiol"},{"key":"1389_CR11","doi-asserted-by":"crossref","unstructured":"Chakraborty J et al. (2018) USP14 Inhibition corrects an in vivo model of impaired mitophagy. EMBO Mol Med 10.","DOI":"10.15252\/emmm.201809014"},{"key":"1389_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","volume":"20","author":"MJ Clague","year":"2019","unstructured":"Clague MJ, Urb\u00e9 S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat Rev Mol Cell Biol. 2019;20:338\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1389_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2018.03.022","volume":"70","author":"KE Coleman","year":"2018","unstructured":"Coleman KE, Huang TT. In a class of its own: A new family of deubiquitinases promotes genome stability. Mol Cell. 2018;70:1\u20133.","journal-title":"Mol Cell"},{"key":"1389_CR14","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1093\/hmg\/ddu244","volume":"23","author":"T Cornelissen","year":"2014","unstructured":"Cornelissen T, et al. The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy. Hum Mol Genet. 2014;23:5227\u201342.","journal-title":"Hum Mol Genet"},{"key":"1389_CR15","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1158\/1078-0432.CCR-13-2658","volume":"20","author":"K Coughlin","year":"2014","unstructured":"Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated dubs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20:3174\u201386.","journal-title":"Clin Cancer Res"},{"key":"1389_CR16","doi-asserted-by":"publisher","first-page":"14506","DOI":"10.1038\/s41598-019-50857-y","volume":"9","author":"MD Cundiff","year":"2019","unstructured":"Cundiff MD, et al. Ubiquitin receptors are required for substrate-mediated activation of the proteasome\u2019s unfolding ability. Sci Rep. 2019;9:14506.","journal-title":"Sci Rep"},{"key":"1389_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/bs.apcsb.2022.05.008","volume":"132","author":"F Di Domenico","year":"2022","unstructured":"Di Domenico F, Lanzillotta C. The disturbance of protein synthesis\/degradation homeostasis is a common trait of age-related neurodegenerative disorders. Adv Protein Chem Struct Biol. 2022;132:49\u201387.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"1389_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00018-024-05246-8","volume":"81","author":"L Ding","year":"2024","unstructured":"Ding L, et al. Usp14 deficiency removes \u03b1-synuclein by regulating S100A8\/A9 in parkinson\u2019s disease. Cell Mol Life Sci. 2024;81:232.","journal-title":"Cell Mol Life Sci"},{"key":"1389_CR19","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.arr.2021.101367","volume":"69","author":"HA Do","year":"2021","unstructured":"Do HA, Baek KH. Cellular functions regulated by deubiquitinating enzymes in neurodegenerative diseases. Ageing Res Rev. 2021;69:101367.","journal-title":"Ageing Res Rev"},{"key":"1389_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/15548627.2015.1009794","volume":"11","author":"TM Durcan","year":"2015","unstructured":"Durcan TM, Fon EA. USP8 and PARK2\/parkin-mediated mitophagy. Autophagy. 2015;11:428\u20139.","journal-title":"Autophagy"},{"key":"1389_CR21","doi-asserted-by":"crossref","unstructured":"Dusek P, Hofer T, Alexander J, Roos PM, Aaseth JO. (2022) Cerebral Iron Deposition in Neurodegeneration. Biomolecules 12.","DOI":"10.3390\/biom12050714"},{"key":"1389_CR22","doi-asserted-by":"publisher","first-page":"117872","DOI":"10.1016\/j.ejmech.2025.117872","volume":"296","author":"AA El-Hamaky","year":"2025","unstructured":"El-Hamaky AA, El-Hamamsy MH, El-Moselhy TF, Sharafeldin N, Tawfik HO. Therapeutic targeting of ubiquitin-specific protease 7 (USP7): mechanistic insights, dysregulation, and advances in drug discovery. Eur J Med Chem. 2025;296:117872.","journal-title":"Eur J Med Chem"},{"key":"1389_CR23","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1038\/s41467-023-42876-1","volume":"14","author":"TZ Fang","year":"2023","unstructured":"Fang TZ, et al. Knockout or Inhibition of USP30 protects dopaminergic neurons in a parkinson\u2019s disease mouse model. Nat Commun. 2023;14:7295.","journal-title":"Nat Commun"},{"key":"1389_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arcmed.2020.09.007","volume":"52","author":"I Fern\u00e1ndez-Cruz","year":"2021","unstructured":"Fern\u00e1ndez-Cruz I, Reynaud E. Proteasome subunits involved in neurodegenerative diseases. Arch Med Res. 2021;52:1\u201314.","journal-title":"Arch Med Res"},{"key":"1389_CR25","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.cmet.2023.10.016","volume":"35","author":"MK Ge","year":"2023","unstructured":"Ge MK, et al. The tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino acid insufficiency. Cell Metabol. 2023;35:2216\u2013e22302218.","journal-title":"Cell Metabol"},{"key":"1389_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13024-024-00756-2","volume":"19","author":"FF Geibl","year":"2024","unstructured":"Geibl FF, et al. \u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in parkinson\u2019s disease. Mol Neurodegener. 2024;19:69.","journal-title":"Mol Neurodegener"},{"key":"1389_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018;17:57\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"1389_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s40001-024-02095-w","volume":"29","author":"D Hou","year":"2024","unstructured":"Hou D, et al. The deubiquitinase OTUD3 stabilizes IRP2 expression to reduce hippocampal neuron ferroptosis via the p53\/PTGS2 pathway to ameliorate cerebral ischemia-reperfusion injury. Eur J Med Res. 2024;29:498.","journal-title":"Eur J Med Res"},{"key":"1389_CR29","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.4161\/cc.20174","volume":"11","author":"OA Issaenko","year":"2012","unstructured":"Issaenko OA, Amerik AY. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle. 2012;11:1804\u201317.","journal-title":"Cell Cycle"},{"key":"1389_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04704-0","volume":"13","author":"F Jia","year":"2022","unstructured":"Jia F, et al. Deubiquitylase OTUD3 prevents parkinson\u2019s disease through stabilizing iron regulatory protein 2. Cell Death Dis. 2022;13:418.","journal-title":"Cell Death Dis"},{"key":"1389_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4155\/ppa-2020-0008","volume":"9","author":"J Joubert","year":"2020","unstructured":"Joubert J. Small-molecule inhibitors of \u03b1-synuclein for the treatment of parkinson\u2019s disease: a patent landscape. Pharm Pat Anal. 2020;9:63\u20135.","journal-title":"Pharm Pat Anal"},{"key":"1389_CR32","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-10-1530","volume":"70","author":"V Kapuria","year":"2010","unstructured":"Kapuria V, et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70:9265\u201376.","journal-title":"Cancer Res"},{"key":"1389_CR33","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.celrep.2018.06.058","volume":"24","author":"E Kim","year":"2018","unstructured":"Kim E, et al. Dual function of USP14 deubiquitinase in cellular proteasomal activity and autophagic flux. Cell Rep. 2018;24:732\u201343.","journal-title":"Cell Rep"},{"key":"1389_CR34","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41418-020-00639-1","volume":"28","author":"L Krassikova","year":"2021","unstructured":"Krassikova L, et al. The deubiquitinase JOSD2 is a positive regulator of glucose metabolism. Cell Death Differ. 2021;28:1091\u2013109.","journal-title":"Cell Death Differ"},{"key":"1389_CR35","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.RA119.009546","volume":"295","author":"R Kumari","year":"2020","unstructured":"Kumari R, et al. Amyloid aggregates of the deubiquitinase OTUB1 are neurotoxic, suggesting that they contribute to the development of Parkinson\u2019s disease. J Biol Chem. 2020;295:3466\u201384.","journal-title":"J Biol Chem"},{"key":"1389_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1021\/acschemneuro.1c00855","volume":"13","author":"R Kumari","year":"2022","unstructured":"Kumari R, Kumar R, Dey AK, Saha S, Maiti TK. S-nitrosylation of OTUB1 alters its stability and Ubc13 binding. ACS Chem Neurosci. 2022;13:1517\u201325.","journal-title":"ACS Chem Neurosci"},{"key":"1389_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2174\/1389203717666160217143721","volume":"18","author":"YC Lee","year":"2017","unstructured":"Lee YC, Hsu SD. Familial mutations and post-translational modifications of UCH-L1 in parkinson\u2019s disease and neurodegenerative disorders. Curr Protein Pept Sci. 2017;18:733\u201345.","journal-title":"Curr Protein Pept Sci"},{"key":"1389_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050829","author":"MM Lewis","year":"2023","unstructured":"Lewis MM, et al. Dopamine D(1) agonists: first potential treatment for late-stage Parkinson\u2019s disease. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13050829.","journal-title":"Biomolecules"},{"key":"1389_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050851","author":"Y Li","year":"2022","unstructured":"Li Y, Li S, Wu H. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11050851.","journal-title":"Cells"},{"key":"1389_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12017-023-08755-0","volume":"25","author":"Y Liang","year":"2023","unstructured":"Liang Y, et al. The role of Ubiquitin-Proteasome system and mitophagy in the pathogenesis of parkinson\u2019s disease. Neuromol Med. 2023;25:471\u201388.","journal-title":"Neuromol Med"},{"key":"1389_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(02)01012-7","volume":"111","author":"Y Liu","year":"2002","unstructured":"Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and parkinson\u2019s disease susceptibility. Cell. 2002;111:209\u201318.","journal-title":"Cell"},{"key":"1389_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41380-021-01233-8","volume":"27","author":"B Liu","year":"2022","unstructured":"Liu B, et al. Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases. Mol Psychiatry. 2022;27:259\u201368.","journal-title":"Mol Psychiatry"},{"key":"1389_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12035-022-03063-3","volume":"60","author":"N Liu","year":"2023","unstructured":"Liu N, Lin MM, Wang Y. The emerging roles of E3 ligases and dubs in neurodegenerative diseases. Mol Neurobiol. 2023;60:247\u201363.","journal-title":"Mol Neurobiol"},{"key":"1389_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116753","volume":"175","author":"L Lu","year":"2024","unstructured":"Lu L, Jifu C, Xia J, Wang J. E3 ligases and dubs target ferroptosis: a potential therapeutic strategy for neurodegenerative diseases. Biomed Pharmacother. 2024a;175:116753.","journal-title":"Biomed Pharmacother"},{"key":"1389_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116753","volume":"175","author":"L Lu","year":"2024","unstructured":"Lu L, Jifu C, Xia J, Wang J. E3 ligases and dubs target ferroptosis: a potential therapeutic strategy for neurodegenerative diseases. Biomed Pharmacother. 2024b;175:116753.","journal-title":"Biomed Pharmacother"},{"key":"1389_CR46","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1021\/acschemneuro.2c00076","volume":"13","author":"S Mandal","year":"2022","unstructured":"Mandal S, Kumar Br P, Alam MT, Tripathi PP, Channappa B. Novel imidazole phenoxyacetic acids as inhibitors of USP30 for neuroprotection implication via the Ubiquitin-Rho-110 fluorometric assay: design, synthesis, and in silico and biochemical assays. ACS Chem Neurosci. 2022;13:1433\u201345.","journal-title":"ACS Chem Neurosci"},{"key":"1389_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.molcel.2010.07.001","volume":"39","author":"ML Matsumoto","year":"2010","unstructured":"Matsumoto ML, et al. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell. 2010;39:477\u201384.","journal-title":"Mol Cell"},{"key":"1389_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081143","author":"S Mauri","year":"2023","unstructured":"Mauri S, et al. USP8 down-regulation promotes Parkin-Independent mitophagy in the Drosophila brain and in human neurons. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12081143.","journal-title":"Cells"},{"key":"1389_CR49","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbapap.2019.03.001","volume":"1867","author":"S Mehra","year":"2019","unstructured":"Mehra S, Sahay S, Maji SK. \u0391-Synuclein misfolding and aggregation: implications in parkinson\u2019s disease pathogenesis. Biochimica et Biophysica Acta (BBA). 2019;1867:890\u2013908.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1389_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2015.01.042","volume":"58","author":"MA Michel","year":"2015","unstructured":"Michel MA, et al. Assembly and specific recognition of k29- and k33-linked polyubiquitin. Mol Cell. 2015;58:95\u2013109.","journal-title":"Mol Cell"},{"key":"1389_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126213","author":"S Moon","year":"2021","unstructured":"Moon S, Muniyappan S, Lee SB, Lee BH. Small-molecule inhibitors targeting Proteasome-Associated deubiquitinases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22126213.","journal-title":"Int J Mol Sci"},{"key":"1389_CR52","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/hmg\/ddh095","volume":"13","author":"JR Morris","year":"2004","unstructured":"Morris JR, Solomon E. BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet. 2004;13:807\u201317.","journal-title":"Hum Mol Genet"},{"key":"1389_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403:293\u2013304.","journal-title":"Lancet"},{"key":"1389_CR54","doi-asserted-by":"crossref","unstructured":"Munavar KF, Lenka N. (2025) Deubiquitinating enzymes at the crossroads of blood-brain barrier integrity and neurodegeneration: mechanistic insights, therapeutic targeting and future directions. Tissue Barriers: 2504738.","DOI":"10.1080\/21688370.2025.2504738"},{"key":"1389_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040651","author":"P Nielsen","year":"2023","unstructured":"Nielsen P, Okarmus J, Meyer M. Role of deubiquitinases in Parkinson\u2019s disease-therapeutic perspectives. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12040651.","journal-title":"Cells"},{"key":"1389_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0006-291X(03)00555-2","volume":"304","author":"K Nishikawa","year":"2003","unstructured":"Nishikawa K, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003;304:176\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"1389_CR57","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1080\/15548627.2019.1656957","volume":"16","author":"K Niu","year":"2020","unstructured":"Niu K, et al. USP33 deubiquitinates PRKN\/parkin and antagonizes its role in mitophagy. Autophagy. 2020;16:724\u201334.","journal-title":"Autophagy"},{"key":"1389_CR58","doi-asserted-by":"publisher","first-page":"592","DOI":"10.5483\/BMBRep.2021.54.12.107","volume":"54","author":"GH Park","year":"2021","unstructured":"Park GH, Park JH, Chung KC. Precise control of mitophagy through ubiquitin proteasome system and deubiquitin proteases and their dysfunction in parkinson\u2019s disease. BMB Rep. 2021;54:592\u2013600.","journal-title":"BMB Rep"},{"key":"1389_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbrc.2023.01.030","volume":"645","author":"SS Park","year":"2023","unstructured":"Park SS, Do HA, Park HB, Choi HS, Baek KH. Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes \u03b1-synuclein. Biochem Biophys Res Commun. 2023;645:124\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"1389_CR60","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/acs.biochem.2c00085","volume":"61","author":"W Pawloski","year":"2022","unstructured":"Pawloski W, Komiyama T, Kougentakis C, Majumdar A, Fushman D. Site-specific detection and characterization of ubiquitin carbamylation. Biochemistry. 2022;61:712\u201321.","journal-title":"Biochemistry"},{"key":"1389_CR61","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","volume":"125","author":"LF Peterson","year":"2015","unstructured":"Peterson LF, et al. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015;125:3588\u201397.","journal-title":"Blood"},{"key":"1389_CR62","doi-asserted-by":"publisher","first-page":"18666","DOI":"10.1073\/pnas.1105725108","volume":"108","author":"R Rott","year":"2011","unstructured":"Rott R, et al. \u0391-synuclein fate is determined by USP9X-regulated monoubiquitination. Proc Natl Acad Sci USA. 2011;108:18666\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1389_CR63","doi-asserted-by":"crossref","unstructured":"Rusilowicz-Jones EV et al. (2020) USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation. Life Sci Alliance 3.","DOI":"10.26508\/lsa.202000768"},{"key":"1389_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00601-1","volume":"9","author":"L Schorova","year":"2023","unstructured":"Schorova L, et al. USP19 deubiquitinase inactivation regulates \u03b1-synuclein ubiquitination and inhibits accumulation of lewy body-like aggregates in mice. NPJ Parkinsons Dis. 2023;9:157.","journal-title":"NPJ Parkinsons Dis"},{"key":"1389_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neuint.2006.07.015","volume":"50","author":"R Setsuie","year":"2007","unstructured":"Setsuie R, et al. Dopaminergic neuronal loss in transgenic mice expressing the parkinson\u2019s disease-associated UCH-L1 I93M mutant. Neurochem Int. 2007;50:119\u201329.","journal-title":"Neurochem Int"},{"key":"1389_CR66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nbd.2018.01.006","volume":"112","author":"K Tanji","year":"2018","unstructured":"Tanji K, et al. YOD1 attenuates neurogenic proteotoxicity through its deubiquitinating activity. Neurobiol Dis. 2018;112:14\u201323.","journal-title":"Neurobiol Dis"},{"key":"1389_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/antib12030043","author":"T Tashima","year":"2023","unstructured":"Tashima T. Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. Antibodies. 2023. https:\/\/doi.org\/10.3390\/antib12030043.","journal-title":"Antibodies"},{"key":"1389_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012105","author":"E Tsefou","year":"2022","unstructured":"Tsefou E, Ketteler R. Targeting deubiquitinating enzymes (DUBs) that regulate mitophagy via direct or indirect interaction with Parkin. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012105.","journal-title":"Int J Mol Sci"},{"key":"1389_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbrc.2013.05.080","volume":"436","author":"H Tsuchiya","year":"2013","unstructured":"Tsuchiya H, Tanaka K, Saeki Y. The parallel reaction monitoring method contributes to a highly sensitive Polyubiquitin chain quantification. Biochem Biophys Res Commun. 2013;436:223\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1389_CR70","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.7150\/thno.72826","volume":"12","author":"A Tyagi","year":"2022","unstructured":"Tyagi A, et al. CRISPR\/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Theranostics. 2022;12:5949\u201370.","journal-title":"Theranostics"},{"key":"1389_CR71","doi-asserted-by":"crossref","unstructured":"Wang X, Liu N, Li N, Lu S, Chai Z. (2025) Mechanistic Insights into the Mechanism of Allosteric Inhibition of Ubiquitin-Specific Protease 7 (USP7). Biomolecules 15.","DOI":"10.3390\/biom15060749"},{"key":"1389_CR72","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41388-024-03009-0","volume":"43","author":"Q Wu","year":"2024","unstructured":"Wu Q, et al. USP26 promotes colorectal cancer tumorigenesis by restraining PRKN-mediated mitophagy. Oncogene. 2024;43:1581\u201393.","journal-title":"Oncogene"},{"key":"1389_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/psyg.12900","volume":"23","author":"X Xing","year":"2023","unstructured":"Xing X, Xu F, Wang Y, Liu H. Role of the OTUB1\/IRF7\/NOX4 axis in oxidative stress injury and inflammatory responses in mice with parkinson\u2019s disease. Psychogeriatrics. 2023;23:32\u201344.","journal-title":"Psychogeriatrics"},{"key":"1389_CR74","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/cr.2014.20","volume":"24","author":"W Yue","year":"2014","unstructured":"Yue W, et al. A small natural molecule promotes mitochondrial fusion through Inhibition of the deubiquitinase USP30. Cell Res. 2014;24:482\u201396.","journal-title":"Cell Res"},{"key":"1389_CR75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fnagi.2016.00303","volume":"8","author":"Q Zheng","year":"2016","unstructured":"Zheng Q, et al. Dysregulation of Ubiquitin-Proteasome system in neurodegenerative diseases. Front Aging Neurosci. 2016;8:303.","journal-title":"Front Aging Neurosci"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01389-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01389-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:04:22Z","timestamp":1762524262000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01389-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1389"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01389-x","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants, human data, or animal experiments, and therefore no approval by the Institutional Review Board of Hangzhou medical college was required for this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors listed have approved the manuscript that is enclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}